{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:12:31Z","timestamp":1792645951920,"version":"4.5.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["13N 13341"],"award-info":[{"award-number":["13N 13341"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s41181-019-0069-0","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T09:02:33Z","timestamp":1564045353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":205,"title":["Targeting of activated fibroblasts for imaging and therapy"],"prefix":"10.1186","volume":"4","author":[{"given":"Thomas","family":"Lindner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Loktev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"69_CR1","doi-asserted-by":"crossref","first-page":"19441","DOI":"10.1074\/jbc.C500092200","volume":"280","author":"K Aertgeerts","year":"2005","unstructured":"Aertgeerts K, Levin I, Shi L, et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem. 2005;280:19441\u20134.","journal-title":"J Biol Chem"},{"key":"69_CR2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1055\/s-0037-1613388","volume":"89","author":"RT Aimes","year":"2003","unstructured":"Aimes RT, Zijlstra A, Hooper JD, et al. Endothelial serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost. 2003;89:561\u201372.","journal-title":"Thromb Haemost"},{"key":"69_CR3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/pros.23162","volume":"76","author":"ES Akinboye","year":"2016","unstructured":"Akinboye ES, Brennen WN, Rosen DM, et al. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidas IV DPPIV using a tandem enzymatic activation strategy. Prostate. 2016;76:703\u201314.","journal-title":"Prostate"},{"key":"69_CR4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1158\/2326-6066.CIR-13-0150","volume":"2","author":"JN Arnold","year":"2014","unstructured":"Arnold JN, Magiera L, Kraman M, Fearon DT. Tumoral immune suppression by macrophages expressing fibroblast activation protein-alpha and heme oxygenase- 1. Cancer Immunol Res. 2014;2:121\u20136.","journal-title":"Cancer Immunol Res"},{"key":"69_CR5","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/carcin\/23.10.1593","volume":"23","author":"VV Artym","year":"2002","unstructured":"Artym VV, Kindzelskii AL, Chen WT, et al. Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton. Carcinogenesis. 2002;23:1593\u2013601.","journal-title":"Carcinogenesis"},{"key":"69_CR6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejcb.2016.07.004","volume":"95","author":"Y Attieh","year":"2016","unstructured":"Attieh Y, Vignjevic DM. The hallmarks of CAFs in cancer invasion. Eur J Cell Biol. 2016;95:493\u2013502.","journal-title":"Eur J Cell Biol"},{"key":"69_CR7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.matbio.2017.12.003","volume":"67","author":"D Averya","year":"2018","unstructured":"Averya D, Govindaraju P, Michele Jacob M, et al. Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts. Matrix Biol. 2018;67:90\u2013106.","journal-title":"Matrix Biol"},{"key":"69_CR8","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1186\/ar2080","volume":"8","author":"S Bauer","year":"2006","unstructured":"Bauer S, Jendro MC, Wadle A, Kleber S, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther. 2006;8:R171.","journal-title":"Arthritis Res Ther"},{"key":"69_CR9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-11-0340","volume":"11","author":"WN Brennen","year":"2012","unstructured":"Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing cells as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012a;11:257\u201366.","journal-title":"Mol Cancer Ther"},{"key":"69_CR10","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djs336","volume":"104","author":"WN Brennen","year":"2012","unstructured":"Brennen WN, Rosen DM, Wang H, et al. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated Prodrug. J Natl Cancer Inst. 2012b;104:1320\u201334.","journal-title":"J Natl Cancer Inst"},{"key":"69_CR11","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/eurheartj\/ehq519","volume":"32","author":"CE Brokopp","year":"2011","unstructured":"Brokopp CE, Schoenauer R, Richards P, et al. Fibroblast activation protein is induced by inlfammation and degrades type 1 collagen in thin-cap fibroatheroma. Eur Heart J. 2011;32:2713\u201322.","journal-title":"Eur Heart J"},{"key":"69_CR12","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1073\/pnas.93.5.1924","volume":"93","author":"DD Brown","year":"1996","unstructured":"Brown DD, Wang Z, Furlow JD, et al. The thyroid hormone-induced tail resorbtion program during Xenopus laevis metamorphosis. Proc Natl Acad Sci U S A. 1996;93:1924\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"69_CR13","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1158\/1535-7163.MCT-15-0647","volume":"1","author":"P Br\u00fcnker","year":"2016","unstructured":"Br\u00fcnker P, Wartha K, Friess T, et al. RG7386, a novel tetravalent FAP-DR5 antibody, effectively triggers FAP-dependent, avidity-driven DR5 hyperclustering and tumor cell apoptosis. Mol Cancer Ther. 2016;1:946\u201357.","journal-title":"Mol Cancer Ther"},{"key":"69_CR14","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1172\/JCI94258","volume":"127","author":"M Chen","year":"2017","unstructured":"Chen M, Lei X, Shi C, et al. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. J Clin Invest. 2017;127:3689\u2013701.","journal-title":"J Clin Invest"},{"key":"69_CR15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1023055600919","volume":"22","author":"WT Chen","year":"2003","unstructured":"Chen WT, Kelly T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev. 2003;22:259\u201369.","journal-title":"Cancer Metastasis Rev"},{"key":"69_CR16","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/bcr3472","volume":"15","author":"J Choi","year":"2013","unstructured":"Choi J, Kim H, Jung WH, et al. Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res. 2013;15:R78.","journal-title":"Breast Cancer Res"},{"key":"69_CR17","first-page":"482","volume":"1","author":"P Cirri","year":"2011","unstructured":"Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side oft he coin. Am J Cancer Res. 2011;1:482\u201397.","journal-title":"Am J Cancer Res"},{"key":"69_CR18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MPA.0b013e31816618ce","volume":"37","author":"SJ Cohen","year":"2008","unstructured":"Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37:154\u20138.","journal-title":"Pancreas."},{"key":"69_CR19","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1021\/jm800390n","volume":"51","author":"BA Connolly","year":"2008","unstructured":"Connolly BA, Sanford DG, Chiluwal AK, Healey SE, Peters DE, Dimare MT, Wu W, Liu Y, Maw H, Zhou Y, Li Y, Jin Z, Sudmeier JL, Lai JH, Bachovchin WW. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem. 2008;51:6005\u201313.","journal-title":"J Med Chem"},{"key":"69_CR20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2013.12.010","volume":"25","author":"E Cortez","year":"2014","unstructured":"Cortez E, Roswall P, Pietras K. Functional subsets of mesenchymal cell types in the tumor microenvironment. Semin Cancer Biol. 2014;25:3\u20139.","journal-title":"Semin Cancer Biol"},{"key":"69_CR21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0344-0338(97)80102-1","volume":"193","author":"B Davidson","year":"1997","unstructured":"Davidson B, Goldberg I, Kopolovic J. Inflammatory response in cervical intraepithelial neoplasia and squamous cell carcinoma of the uterine cervix. Pathol Res Pract. 1997;193:491\u20135.","journal-title":"Pathol Res Pract"},{"key":"69_CR22","first-page":"1","volume":"5","author":"H Dolznig","year":"2005","unstructured":"Dolznig H, Schweifer N, Puri C, et al. Characterization of cancer stroma cells: in silco analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun. 2005;5:1\u201310.","journal-title":"Cancer Immun"},{"key":"69_CR23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clon.2009.04.007","volume":"21","author":"RM Eager","year":"2009","unstructured":"Eager RM, Cunningham CC, Senzer N, Richards DA, Raju RN, Jones B, et al. Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. Clin Oncol. 2009a;21:464\u201372.","journal-title":"Clin Oncol"},{"key":"69_CR24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1471-2407-9-263","volume":"9","author":"RM Eager","year":"2009","unstructured":"Eager RM, Cunningham CC, Senzer NN, Stephenson J, Anthony SP, O\u2019Day SJ, et al. Phase II assessment of talabostat and cis- platin in second-line stage IV melanoma. BMC Cancer. 2009b;9:263.","journal-title":"BMC Cancer"},{"key":"69_CR25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2017.05.022","volume":"809","author":"C Egger","year":"2017","unstructured":"Egger C, Cannet C, Gerard C, et al. Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis. Eur J Pharmacol. 2017;809:64\u201372.","journal-title":"Eur J Pharmacol"},{"key":"69_CR26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1042\/BST20160387","volume":"45","author":"B Erdogan","year":"2017","unstructured":"Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signalling and extracellular matrix remodelling to regulate tumor metastasis. Biochem Soc Trans. 2017;45:229\u201336.","journal-title":"Biochem Soc Trans"},{"key":"69_CR27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccr.2009.12.041","volume":"17","author":"N Erez","year":"2010","unstructured":"Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010;17:135\u201347.","journal-title":"Cancer Cell"},{"key":"69_CR28","doi-asserted-by":"crossref","first-page":"16007","DOI":"10.1038\/mto.2016.7","volume":"3","author":"J Fang","year":"2016","unstructured":"Fang J, Hu B, Li S, et al. A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma. Mol Ther Oncolytics. 2016b;3:16007.","journal-title":"Mol Ther Oncolytics"},{"key":"69_CR29","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.29831","volume":"138","author":"J Fang","year":"2016","unstructured":"Fang J, Xiao L, Joo KI, et al. A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice. Int J Cancer. 2016a;138:1013\u201323.","journal-title":"Int J Cancer"},{"key":"69_CR30","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110:20212\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"69_CR31","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1158\/1078-0432.CCR-12-0644","volume":"18","author":"E Fischer","year":"2012","unstructured":"Fischer E, Chaitanya K, Wuest T, et al. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin Cancer Res. 2012;18:6208\u201318.","journal-title":"Clin Cancer Res"},{"key":"69_CR32","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1073\/pnas.88.4.1556","volume":"88","author":"GR Flentke","year":"1991","unstructured":"Flentke GR, Munoz E, Huber BT, Plaut AG, Kettner CA, Bachovchin WW. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci U S A. 1991;88:1556\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"69_CR33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1349-7006.2012.02209.x","volume":"103","author":"Y Fuyuhiro","year":"2012","unstructured":"Fuyuhiro Y, Yashiro M, Noda S, et al. Cancer-associated orthotopic myofibroblasts stimulate the motility of gastric carcinoma cells. Cancer Sci. 2012;103:797\u2013805.","journal-title":"Cancer Sci"},{"key":"69_CR34","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1242\/jcs.072900","volume":"123","author":"MQ Gao","year":"2010","unstructured":"Gao MQ, Kim BG, Kang S, et al. Stromal fibroblasts from the interface zone of human breast carcinomas indcue an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci. 2010;123:3507\u201314.","journal-title":"J Cell Sci"},{"key":"69_CR35","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","volume":"87","author":"P Garin-Chesa","year":"1990","unstructured":"Garin-Chesa P, Old LJ, Rettig WJ. Cell-surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87:7235\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"69_CR36","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1101\/gad.279737.116","volume":"30","author":"P Gascard","year":"2017","unstructured":"Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2017;30:1002\u201319.","journal-title":"Genes Dev"},{"key":"69_CR37","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"F Giesel","year":"2019","unstructured":"Giesel F, Kratochwil C, Lindner T, et al. FAPI-PET\/CT: biodistribution and preliminary dosimetry estimate of two DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019a;60:386\u201392.","journal-title":"J Nucl Med"},{"key":"69_CR38","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s00259-019-04346-z","volume":"46","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Heussel CP, Lindner T, et al. FAPI-PET\/CT improves staging in a lung cancer patient with cerebral metastasis. Eur J Nucl Med Mol Imaging. 2019b;46:1754\u20135.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"69_CR39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0925-4439(97)00032-X","volume":"1361","author":"LA Goldstein","year":"1997","unstructured":"Goldstein LA, Ghersi G, Piniero-Sanchez ML, et al. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochim Biophys Acta. 1997;1361:11\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"69_CR40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/A:1025493605850","volume":"20","author":"J Goodman","year":"2003","unstructured":"Goodman J, Rozypal T, Kelly T, et al. Seprase, a membrane-bound protease alleviates the serumgrowth requirement of human breast cancer cells. Clin Exp Metastasis. 2003;20:459\u201370.","journal-title":"Clin Exp Metastasis"},{"key":"69_CR41","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.4161\/cc.21384","volume":"11","author":"CD Guido","year":"2012","unstructured":"Guido CD, Whitaker-Mendes C, Capparelli R, et al. Metabolic reprogramming of cancer \u2013associated fibroblasts by TGF\u03b2 drives tumor growth: connecting TGF\u03b2 -signalling with \u2018Warburg-like\u2019 cancer metabolism and L-lactate production. Cell Cycle. 2012;11:3019\u201335.","journal-title":"Cell Cycle"},{"key":"69_CR42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","volume":"8","author":"EJ Hamson","year":"2014","unstructured":"Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, actiivities, expression and targeting for cancer therapy. Proteomics Clin Apll. 2014;8:454\u201363.","journal-title":"Proteomics Clin Apll"},{"key":"69_CR43","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1158\/1078-0432.CCR-06-1746","volume":"13","author":"LR Henry","year":"2007","unstructured":"Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13:1736\u201341.","journal-title":"Clin Cancer Res"},{"key":"69_CR44","first-page":"44","volume":"26","author":"RD Hofheinz","year":"2003","unstructured":"Hofheinz RD, al- Batran F, Hartmann G, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 2003;26:44\u20138.","journal-title":"Onkologie"},{"key":"69_CR45","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/1061186X.2010.511225","volume":"19","author":"S Huang","year":"2011","unstructured":"Huang S, Fang R, Xu J, et al. Evaluation of the tumor targeting of a FAPalpha based doxorubicin prodrug. J Drug Target. 2011a;19:487\u201396.","journal-title":"J Drug Target"},{"key":"69_CR46","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/mto.2015.3","volume":"2","author":"T Huang","year":"2015","unstructured":"Huang T, Wang H, Chen NG, et al. Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy. Mol Ther Oncolytics. 2015;2:15003.","journal-title":"Mol Ther Oncolytics"},{"key":"69_CR47","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10585-011-9392-x","volume":"28","author":"Y Huang","year":"2011","unstructured":"Huang Y, Simms AE, Mazur A, et al. Fibroblast activation protein-\u03b1 promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis. 2011b;28:567\u201379.","journal-title":"Clin Exp Metastasis"},{"key":"69_CR48","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1158\/0008-5472.CAN-03-3184","volume":"64","author":"Y Huang","year":"2004","unstructured":"Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res. 2004;64:2712\u20136.","journal-title":"Cancer Res"},{"key":"69_CR49","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.addr.2015.07.007","volume":"99","author":"G Ischii","year":"2016","unstructured":"Ischii G, Ochiai A, Neri S. Phenotypic and functional heterogenity of cancer-associated fibroblast within the tumor micorenvironment. Adv Drug Deliv Rev. 2016;99:186\u201396.","journal-title":"Adv Drug Deliv Rev"},{"key":"69_CR50","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2174\/156652412803833607","volume":"12","author":"M Jacob","year":"2012","unstructured":"Jacob M, Chang L, Pure E. Fibroblast activation protein in remodelling tissues. Curr Mol Med. 2012;12:1220\u201343.","journal-title":"Curr Mol Med"},{"key":"69_CR51","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","volume":"4","author":"K Jansen","year":"2013","unstructured":"Jansen K, Heirbaut L, Cheng JD, et al. Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. ACS Med Chem Lett. 2013;4:491\u20136.","journal-title":"ACS Med Chem Lett"},{"key":"69_CR52","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/jm500031w","volume":"57","author":"K Jansen","year":"2014","unstructured":"Jansen K, Heirbaut L, Verkerk R, et al. Extended Structure\u2013Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP). J Med Chem. 2014;57:3053\u201374.","journal-title":"J Med Chem"},{"key":"69_CR53","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1309\/AJCP86PPBNGOHNNL","volume":"131","author":"MJ Ju","year":"2009","unstructured":"Ju MJ, Qiu SJ, Fan J, et al. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol. 2009;131:498\u2013510.","journal-title":"Am J Clin Pathol"},{"key":"69_CR54","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/14728222.2017.1370455","volume":"10","author":"L Juillerat-Jeanneret","year":"2017","unstructured":"Juillerat-Jeanneret L, Tafelmeyer P, Golshayan D. Fibroblast activation protein-a in fibrinogenic disorders and cancer: more than a prolyl-specif peptidase? Expert Opin Ther Targets. 2017;10:977\u201391.","journal-title":"Expert Opin Ther Targets"},{"key":"69_CR55","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/mt.2013.110","volume":"21","author":"S Kakarla","year":"2013","unstructured":"Kakarla S, Chow K, Mata M, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013;21:1611\u201320.","journal-title":"Mol Ther"},{"key":"69_CR56","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582\u201398.","journal-title":"Nat Rev Cancer"},{"key":"69_CR57","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejmech.2016.12.056","volume":"127","author":"MR Ke","year":"2017","unstructured":"Ke MR, Chen SF, Peng XH, et al. A tumor-targeted activable phtalocyanine-tetrapeptide-doxorubicin conjugate for synergistic chemo-photodynamic therapy. Eur J Med Chem. 2017;127:200\u20139.","journal-title":"Eur J Med Chem"},{"key":"69_CR58","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/j.1742-4658.2011.08051.x","volume":"278","author":"FM Keane","year":"2011","unstructured":"Keane FM, Nadvi NA, Yao TW, Gorrell MD, Neuropeptide Y. B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein alpha. FEBS J. 2011;278:1316\u201332.","journal-title":"FEBS J"},{"key":"69_CR59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drup.2005.03.002","volume":"8","author":"T Kelly","year":"2005","unstructured":"Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26). Cell-surface proteases that activate cell signalling and are potential targets for cancer therapy. Drug Resist Updat. 2005;8:51\u20138.","journal-title":"Drug Resist Updat"},{"key":"69_CR60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/B978-0-12-394308-8.00003-0","volume":"297","author":"T Kelly","year":"2012","unstructured":"Kelly T, Huang Y, Simms AE, et al. Fibroblast activation protein-a: a key modulator oft he microenvironment in multiple pathologies. Int Review Cell MolBiol. 2012;297:83\u2013116.","journal-title":"Int Review Cell MolBiol"},{"issue":"2","key":"69_CR61","doi-asserted-by":"publisher","first-page":"e0192157","DOI":"10.1371\/journal.pone.0192157","volume":"13","author":"TK Kilvaer","year":"2018","unstructured":"Kilvaer TK, Rakaee M, Hellevik T, et al. Tissue analyses reveal a potential immune- adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer. PLoS One. 2018;13(2):e0192157. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0192157\n                    \n                  .","journal-title":"PLoS One"},{"key":"69_CR62","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.yexcr.2015.05.016","volume":"335","author":"SA Kim","year":"2015","unstructured":"Kim SA, Lee EK, Kuh HJ. Co-culture of 3D tumor spheroids with fibroblasts as a model for epithelial-mesenchymal transition in vitro. Exp Cell Res. 2015;335:187\u201396.","journal-title":"Exp Cell Res"},{"key":"69_CR63","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/0008-5472.CAN-05-3260","volume":"66","author":"MI Koukourakis","year":"2006","unstructured":"Koukourakis MI, Giatromanolaki A, Harris AL, et al. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006;66:632\u20137.","journal-title":"Cancer Res"},{"key":"69_CR64","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1126\/science.1195300","volume":"330","author":"M Kraman","year":"2010","unstructured":"Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330:827\u201330.","journal-title":"Science"},{"issue":"6","key":"69_CR65","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, et al. FAPI-PET\/CT: Mean intensity of tracer-uptake (SUV) in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801\u20135.","journal-title":"J Nucl Med"},{"key":"69_CR66","doi-asserted-by":"crossref","first-page":"778","DOI":"10.2967\/jnumed.114.152959","volume":"56","author":"P Laverman","year":"2015","unstructured":"Laverman P, van der Geest T, Terry SY, et al. Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis. J Nucl Med. 2015;56:778\u201383.","journal-title":"J Nucl Med"},{"key":"69_CR67","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1535-7163.MCT-08-1170","volume":"8","author":"AM LeBeau","year":"2009","unstructured":"LeBeau AM, Nathaniel Brennen WN, Aggarwal S, et al. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol Cancer Ther. 2009;8:1378\u201386.","journal-title":"Mol Cancer Ther"},{"key":"69_CR68","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-05-2805","volume":"65","author":"J Lee","year":"2005","unstructured":"Lee J, Fassnacht M, Nair S. Targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 2005;65:11156\u201363.","journal-title":"Cancer Res"},{"key":"69_CR69","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1182\/blood-2003-12-4240","volume":"103","author":"KN Lee","year":"2004","unstructured":"Lee KN, Jackson KW, Christiansen VJ, et al. A novel plasma proteinase potentiates alpha 2-antiplasmin inhibition of fibrin digestion. Blood. 2004;103:3783\u20138.","journal-title":"Blood"},{"key":"69_CR70","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/hep.510290631","volume":"29","author":"MT Levy","year":"1999","unstructured":"Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology. 1999;29:1768\u201378.","journal-title":"Hepatology"},{"key":"69_CR71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1034\/j.1600-0676.2002.01503.x","volume":"22","author":"MT Levy","year":"2002","unstructured":"Levy MT, McCaughan GW, Marinos G, et al. Intrahepatic expression of the hepatic stellate marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver Int. 2002;22:93\u2013101.","journal-title":"Liver Int"},{"key":"69_CR72","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.3892\/mmr.2016.4868","volume":"13","author":"M Li","year":"2016","unstructured":"Li M, Li M, Yin T, et al. Targeting of cancer-associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment. Mol Med Rep. 2016;13:2476\u201384.","journal-title":"Mol Med Rep"},{"key":"69_CR73","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, et al. Development of quinoline based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415\u201322.","journal-title":"J Nucl Med"},{"key":"69_CR74","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","volume":"75","author":"A Lo","year":"2015","unstructured":"Lo A, Wang LCS, Scholler J, et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res. 2015;75:2800\u201310.","journal-title":"Cancer Res"},{"key":"69_CR75","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1172\/JCI26532","volume":"116","author":"M Loeffler","year":"2006","unstructured":"Loeffler M, Kr\u00fcger JA, Niethammer AG, et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest. 2006;116:1955\u201362.","journal-title":"J Clin Invest"},{"key":"69_CR76","doi-asserted-by":"publisher","unstructured":"Loktev A, Lindner T, Burger EM, et al. Development of novel FAP-targeted radiotracers with improved tumor retention. J Nucl Med. 2019. \n                    https:\/\/doi.org\/10.2967\/jnumed.118.224469\n                    \n                  .","DOI":"10.2967\/jnumed.118.224469"},{"key":"69_CR77","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev A, Lindner T, Mier W, et al. A new method for tumor imaging by targeting cancer associated fibroblasts. J Nucl Med. 2018;59:1423\u20139.","journal-title":"J Nucl Med"},{"key":"69_CR78","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.4161\/cc.10.15.16585","volume":"10","author":"UE Martinez-Outschoorn","year":"2012","unstructured":"Martinez-Outschoorn UE, Lin Z, Trimmer N, et al. Cancer cells metabolically \u2018fertilize\u2019 the tumor microenvironment with hydrogen peroxide driving the Warburg effect: implications for PET imaging of human tumors. Cell Cycle. 2012;10:2504\u201320.","journal-title":"Cell Cycle"},{"key":"69_CR79","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3390\/molecules20022081","volume":"20","author":"R Meletta","year":"2015","unstructured":"Meletta R, Muller Herde A, Chiotellis A, et al. Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging. Molecules. 2015;20:2081\u201399.","journal-title":"Molecules."},{"key":"69_CR80","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1515\/bc.2010.119","volume":"392","author":"R Mentlein","year":"2011","unstructured":"Mentlein R, Hattermann K, Hemion C, et al. Expression and role of the cell surface protease seprase\/fibroblast activation protein alpha (FAP-alpha) in astroglial tumors. Biol Chem. 2011;392:199\u2013207.","journal-title":"Biol Chem"},{"key":"69_CR81","doi-asserted-by":"crossref","first-page":"24947","DOI":"10.1074\/jbc.274.35.24947","volume":"274","author":"SC Mueller","year":"1999","unstructured":"Mueller SC, Ghersi G, Akiyama SK, et al. A novel protease-docking function of integrin at invadopodia. J Biol Chem. 1999;274:24947\u201352.","journal-title":"J Biol Chem"},{"key":"69_CR82","doi-asserted-by":"crossref","first-page":"10801","DOI":"10.1038\/s41598-017-09790-1","volume":"7","author":"CK Nagaraju","year":"2017","unstructured":"Nagaraju CK, Dries E, Popovic N, et al. Global fibroblast activation throughout the left ventricle but localized fibrosis after myocardial infarction. Sci Rep. 2017;7:10801.","journal-title":"Sci Rep"},{"key":"69_CR83","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4161\/cbt.6.11.4874","volume":"6","author":"K Narra","year":"2007","unstructured":"Narra K, Mullins SR, Lee H-O, Strzemkowski-Brun B, Maga-long K, Christiansen VJ, et al. Phase II trial of single agent Val- boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007;6:1691\u20139.","journal-title":"Cancer Biol Ther"},{"key":"69_CR84","first-page":"445","volume":"45","author":"J Niedermeyer","year":"2001","unstructured":"Niedermeyer J, Garin-Chesa P, Kriz M, et al. Expression of the fibroblast activation protein during mouse embryo development. Int J Dev Biol. 2001;45:445\u20137.","journal-title":"Int J Dev Biol"},{"key":"69_CR85","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/MCB.20.3.1089-1094.2000","volume":"20","author":"J Niedermeyer","year":"2000","unstructured":"Niedermeyer J, Kriz M, Hilberg F, et al. Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol. 2000;20:1089\u201394.","journal-title":"Mol Cell Biol"},{"key":"69_CR86","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/(SICI)1097-0215(19970502)71:3<383::AID-IJC14>3.0.CO;2-H","volume":"71","author":"J Niedermeyer","year":"1997","unstructured":"Niedermeyer J, Scanlan MJ, Garin-Chesa P, et al. Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int J Cancer. 1997;71:383\u20139.","journal-title":"Int J Cancer"},{"key":"69_CR87","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20140692","volume":"211","author":"D \u00d6hlund","year":"2014","unstructured":"\u00d6hlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211:1503\u201323.","journal-title":"J Exp Med"},{"key":"69_CR88","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-07-5211","volume":"14","author":"E Ostermann","year":"2008","unstructured":"Ostermann E, Garin-Chesa P, Heider KH, et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res. 2008;14:4584\u201392.","journal-title":"Clin Cancer Res"},{"key":"69_CR89","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC Ozdemir","year":"2014","unstructured":"Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719\u201334.","journal-title":"Cancer Cell"},{"key":"69_CR90","doi-asserted-by":"crossref","first-page":"36505","DOI":"10.1074\/jbc.274.51.36505","volume":"274","author":"JE Park","year":"1999","unstructured":"Park JE, Lenter MC, Zimmermann RN, et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999;274:36505\u201312.","journal-title":"J Biol Chem"},{"key":"69_CR91","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.4161\/cc.8.23.10238","volume":"8","author":"S Pavlides","year":"2009","unstructured":"Pavlides S, Whitaker-Menezes R, Castello-Cros N, et al. the reverse Warburg effect:aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8:3984\u20134001.","journal-title":"Cell Cycle"},{"key":"69_CR92","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1365-2141.2009.07696.x","volume":"145","author":"A Pennisi","year":"2009","unstructured":"Pennisi A, Li X, Ling W, et al. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. Br J Haematol. 2009;145:775\u201387.","journal-title":"Br J Haematol"},{"key":"69_CR93","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1074\/jbc.272.12.7595","volume":"272","author":"ML Piniero-Sanchez","year":"1997","unstructured":"Piniero-Sanchez ML, Goldstein LA, Dodt J, et al. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem. 1997;272:7595\u2013601.","journal-title":"J Biol Chem"},{"key":"69_CR94","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1021\/jm400351a","volume":"56","author":"SE Poplawski","year":"2013","unstructured":"Poplawski SE, Lai JH, Li Y, et al. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013;56:3467\u201377.","journal-title":"J Med Chem"},{"key":"69_CR95","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","volume":"37","author":"E Pure","year":"2018","unstructured":"Pure E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343\u201357.","journal-title":"Oncogene"},{"key":"69_CR96","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/2326-6066.CIR-16-0011","volume":"4","author":"E Pure","year":"2016","unstructured":"Pure E, Lo A. Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors? Cancer Immunol Res. 2016;4:269\u201378.","journal-title":"Cancer Immunol Res"},{"key":"69_CR97","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.85.9.3110","volume":"85","author":"WJ Rettig","year":"1988","unstructured":"Rettig WJ, Garin-Chesa P, Beresford HR, Oettegen HF, et al. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A. 1988;85:3110\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"69_CR98","first-page":"3327","volume":"53","author":"WJ Rettig","year":"1993","unstructured":"Rettig WJ, Garin-Chesa P, Healey JH, et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 1993;53:3327\u201335.","journal-title":"Cancer Res"},{"key":"69_CR99","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ijc.2910580314","volume":"58","author":"WJ Rettig","year":"1994","unstructured":"Rettig WJ, Su SL, Fortunato SR, et al. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int J Cancer. 1994;58:385\u201392.","journal-title":"Int J Cancer"},{"key":"69_CR100","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","volume":"91","author":"MJ Scanlan","year":"1994","unstructured":"Scanlan MJ, Raj BK, Calvo B, et al. Molecular cloning of fibroblast activation protein alpha, a member oft he serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A. 1994;91:5657\u201361.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"69_CR101","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","volume":"11","author":"PC Schuberth","year":"2013","unstructured":"Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med. 2013;11:187.","journal-title":"J Transl Med"},{"key":"69_CR102","first-page":"1639","volume":"9","author":"AM Scott","year":"2003","unstructured":"Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9:1639\u201347.","journal-title":"Clin Cancer Res"},{"key":"69_CR103","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2125.2001.01335.x","volume":"51","author":"P Tanswell","year":"2001","unstructured":"Tanswell P, Garin-Chesa P, Rettig WJ, et al. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. Br J Clin Pharmacol. 2001;51:177\u201380.","journal-title":"Br J Clin Pharmacol"},{"key":"69_CR104","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.advms.2015.04.006","volume":"60","author":"V Teichgr\u00e4ber","year":"2015","unstructured":"Teichgr\u00e4ber V, Monasterio C, Chaitanya K, et al. Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro. Adv Med Sci. 2015;60:264\u201372.","journal-title":"Adv Med Sci"},{"key":"69_CR105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.yjmcc.2015.08.016","volume":"87","author":"J Tillmanns","year":"2015","unstructured":"Tillmanns J, Hoffmann D, Habbaba Y, et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. J Mol Cell Cardiol. 2015;87:194\u2013203.","journal-title":"J Mol Cell Cardiol"},{"key":"69_CR106","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125\u201335.","journal-title":"J Exp Med"},{"key":"69_CR107","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nri3902","volume":"15","author":"SJ Turley","year":"2015","unstructured":"Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvi- ronment. Nat Rev Immunol. 2015;15:669\u201382.","journal-title":"Nat Rev Immunol"},{"key":"69_CR108","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/jth.12396","volume":"11","author":"S Uitte de Willige","year":"2013","unstructured":"Uitte de Willige S, Malfliet JJ, Janssen HL, Leebeek FW, Rijken DC. Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis. J Thromb Haemost. 2013;11:2029\u201336.","journal-title":"J Thromb Haemost"},{"key":"69_CR109","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2967\/jnumed.116.177931","volume":"58","author":"T van der Geest","year":"2017","unstructured":"van der Geest T, Laverman P, Gerrits D, et al. Liposomal treatment of experimental arthritis can be monitored noninvasively with a radiolabeled anti-fibroblast activation protein antibody. J Nucl Med. 2017;58:151\u20135.","journal-title":"J Nucl Med"},{"key":"69_CR110","doi-asserted-by":"crossref","unstructured":"Varasteh Z, Robu S, Braeuer M, et al. Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labelled fibroblast activation protein inhibitor FAPI-04. J Nucl Med. 2019;60: in press","DOI":"10.1055\/s-0039-1683486"},{"key":"69_CR111","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejphar.2017.09.016","volume":"815","author":"J Wang","year":"2017","unstructured":"Wang J, Li Q, Li X, et al. A novel FAP\u03b1-based Z-Gly-Pro epirubicin prodrug for improving tumortargeting Chemotherapy. Eur J Pharmacol. 2017;815:166\u201372.","journal-title":"Eur J Pharmacol"},{"key":"69_CR112","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LCS Wang","year":"2014","unstructured":"Wang LCS, Lo A, Scholler J. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2:154\u201366.","journal-title":"Cancer Immunol Res"},{"key":"69_CR113","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.2741\/2918","volume":"13","author":"XM Wang","year":"2008","unstructured":"Wang XM, Yao TW, Nadvi NA, et al. Fibroblast activation protein and chronic liver disease. Front Biosci. 2008;13:3168\u201380.","journal-title":"Front Biosci"},{"key":"69_CR114","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/hep.20853","volume":"42","author":"XM Wang","year":"2005","unstructured":"Wang XM, Yu DM, McCaughan GW, et al. Fibroblast activation protein increases apoptosis, cell adhesion and migration by the LX-2 human stellate cell line. Hepatology. 2005;42:935\u201345.","journal-title":"Hepatology"},{"key":"69_CR115","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.1994.12.6.1193","volume":"12","author":"S Welt","year":"1994","unstructured":"Welt S, Divgi CR, Scott AM, et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol. 1994;12:1193\u2013203.","journal-title":"J Clin Oncol"},{"key":"69_CR116","first-page":"6111","volume":"16","author":"N Wild","year":"2010","unstructured":"Wild N, Andres H, Rollinger W, et al. A combination of serum markers for the early detection of colorectal cancer. Cancer Res. 2010;16:6111\u201321.","journal-title":"Cancer Res"},{"key":"69_CR117","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0168-1656(01)00355-8","volume":"92","author":"T W\u00fcst","year":"2001","unstructured":"W\u00fcst T, Moosmayer D, Pfizenmaier K. Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein. J Biotechnol. 2001;92:159\u201368.","journal-title":"J Biotechnol"},{"key":"69_CR118","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/08923973.2016.1269337","volume":"39","author":"Q Xia","year":"2017","unstructured":"Xia Q, Geng F, Zhang FF, et al. Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein \u03b1-based vaccine in tumor-bearing mice with murine breast carcinoma. Immunopharmacol Immunotoxicol. 2017;39:37\u201344.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"69_CR119","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/bjc.2013.768","volume":"110","author":"Y Yu","year":"2014","unstructured":"Yu Y, Xiao CH, Tan LD, et al. Cancer-associated fibroblasts induce epitheial-mesenchymal transition of breast cancer cells hrough paracrine TGF\u03b2 signalling. Br J Cancer. 2014;110:724\u201332.","journal-title":"Br J Cancer"},{"key":"69_CR120","first-page":"1154","volume":"2","author":"J Zhang","year":"2010","unstructured":"Zhang J, Valianou M, Cheng JD. Identification and characterization of the promoter of fibroblast activation protein. Front Biosci. 2010;2:1154\u201363.","journal-title":"Front Biosci"},{"key":"69_CR121","doi-asserted-by":"crossref","unstructured":"Zhang Y, Ertl HC. Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors. Oncotarget. 2016;7:23282\u201399.","DOI":"10.18632\/oncotarget.7818"},{"key":"69_CR122","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2011.01.011","volume":"303","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Tang H, Cai J, et al. Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett. 2011;303:47\u201355.","journal-title":"Cancer Lett"},{"key":"69_CR123","unstructured":"Zimmermann C, Babich JW, Joyal J, Marquis J, Wang J. Selective seprase inhibitors. Patent US 2010\/0098633 A1. 2010."},{"key":"69_CR124","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1139\/y03-006","volume":"81","author":"Z Zukowska","year":"2003","unstructured":"Zukowska Z, Pons J, Lee EW, et al. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessel and immune system? J Physiol Pharmacol. 2003;81:89\u201394.","journal-title":"J Physiol Pharmacol"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-019-0069-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s41181-019-0069-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-019-0069-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T19:12:25Z","timestamp":1595531545000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-019-0069-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1186\/s41181-019-0069-0","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,25]]},"assertion":[{"value":"5 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Patent application (EP 18155420.5) for quinolone based FAP targeting agents for imaging and therapy in nuclear medicine (UH, AL, and TL).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}